471 related articles for article (PubMed ID: 19170587)
21. [Rivaroxaban in the prevention and treatment of thromboembolic disorders].
Helbing T; Bode C; Moser M
Hamostaseologie; 2012; 32(3):195-202. PubMed ID: 22777255
[TBL] [Abstract][Full Text] [Related]
22. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
23. New oral anticoagulants: will they replace warfarin?
Little JW
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 May; 113(5):575-80. PubMed ID: 22668618
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban: practical considerations for ensuring safety and efficacy.
Smythe MA; Fanikos J; Gulseth MP; Wittkowsky AK; Spinler SA; Dager WE; Nutescu EA
Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
[TBL] [Abstract][Full Text] [Related]
25. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Ageno W
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
[TBL] [Abstract][Full Text] [Related]
27. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Sarich TC; Peters G; Berkowitz SD; Misselwitz F; Nessel CC; Burton P; Cook-Bruns N; Lensing AW; Haskell L; Perzborn E; Kubitza D; Moore KT; Jalota S; Weber J; Pan G; Sun X; Westermeier T; Nadel A; Oppenheimer L; DiBattiste PM
Ann N Y Acad Sci; 2013 Jul; 1291():42-55. PubMed ID: 23701516
[TBL] [Abstract][Full Text] [Related]
29. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
Schellong S
Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
[TBL] [Abstract][Full Text] [Related]
32. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
33. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
Steffel J; Lüscher TF
J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):616-23. PubMed ID: 19561526
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Gopalakrishnan L; Kumar V; Kohli P; Singh P; Rastogi U; Gibson CM
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):889-900. PubMed ID: 22577900
[TBL] [Abstract][Full Text] [Related]
35. FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery.
Aalbers J
Cardiovasc J Afr; 2011; 22(4):218. PubMed ID: 21881694
[No Abstract] [Full Text] [Related]
36. Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Perzborn E
Hamostaseologie; 2009 Aug; 29(3):260-7. PubMed ID: 19644596
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Kwong LM
Orthopedics; 2012 Jun; 35(6):e932-8;discussion e939. PubMed ID: 22691670
[TBL] [Abstract][Full Text] [Related]
38. Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.
Imberti D; Prisco D
Pathophysiol Haemost Thromb; 2008; 36(5):217-26. PubMed ID: 19996630
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Kreutz R
Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
[TBL] [Abstract][Full Text] [Related]
40. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Komotar RJ; Starke RM; Connolly ES
Neurosurgery; 2008 Oct; 63(4):N10-1. PubMed ID: 18981864
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
